MX2021013662A - Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. - Google Patents

Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.

Info

Publication number
MX2021013662A
MX2021013662A MX2021013662A MX2021013662A MX2021013662A MX 2021013662 A MX2021013662 A MX 2021013662A MX 2021013662 A MX2021013662 A MX 2021013662A MX 2021013662 A MX2021013662 A MX 2021013662A MX 2021013662 A MX2021013662 A MX 2021013662A
Authority
MX
Mexico
Prior art keywords
heteroarylaminopyrimidine
amide
methods
autophagy inhibitors
autophagy
Prior art date
Application number
MX2021013662A
Other languages
English (en)
Inventor
Daniel L Flynn
Lakshminarayana Vogeti
Yu Mi Ahn
Timothy Caldwell
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Publication of MX2021013662A publication Critical patent/MX2021013662A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

En el presente documento se describen compuestos que son inhibidores de la autofagia y su uso en el tratamiento de trastornos tales como cánceres.
MX2021013662A 2019-05-10 2020-05-08 Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. MX2021013662A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962846260P 2019-05-10 2019-05-10
US201962846264P 2019-05-10 2019-05-10
US201962911736P 2019-10-07 2019-10-07
US201962911733P 2019-10-07 2019-10-07
PCT/US2020/032090 WO2020231808A1 (en) 2019-05-10 2020-05-08 Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021013662A true MX2021013662A (es) 2022-03-11

Family

ID=70847594

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013662A MX2021013662A (es) 2019-05-10 2020-05-08 Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.

Country Status (25)

Country Link
US (2) US11518758B2 (es)
EP (2) EP3966206B1 (es)
JP (1) JP2022531932A (es)
KR (1) KR20220019696A (es)
CN (1) CN114072397A (es)
AU (1) AU2020274011B2 (es)
BR (1) BR112021022576A2 (es)
CA (1) CA3139120A1 (es)
CL (1) CL2021002953A1 (es)
CO (1) CO2021016765A2 (es)
DK (1) DK3966206T3 (es)
ES (1) ES2962852T3 (es)
FI (1) FI3966206T3 (es)
HR (1) HRP20231310T1 (es)
IL (1) IL287795A (es)
LT (1) LT3966206T (es)
MX (1) MX2021013662A (es)
PE (1) PE20220592A1 (es)
PL (1) PL3966206T3 (es)
PT (1) PT3966206T (es)
RS (1) RS64755B1 (es)
SG (1) SG11202112171XA (es)
SI (1) SI3966206T1 (es)
TW (1) TW202108574A (es)
WO (1) WO2020231808A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3790551A4 (en) 2018-05-07 2022-03-09 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
FI3902547T3 (fi) 2018-12-28 2023-12-05 Deciphera Pharmaceuticals Llc Csf1r-inhibiittoreita käytettäväksi syövän hoitamisessa
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
TW202108573A (zh) 2019-05-10 2021-03-01 美商迪賽孚爾製藥有限公司 苯基胺基嘧啶醯胺自噬抑制劑及其使用方法
AU2020274011B2 (en) * 2019-05-10 2024-02-15 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PE20221083A1 (es) 2019-06-17 2022-07-05 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
MX2022003537A (es) 2019-09-24 2022-07-11 Mirati Therapeutics Inc Terapias de combinacion.
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors
CA3163051A1 (en) 2019-12-30 2021-07-08 Michael D. Kaufman Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
KR20220123057A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 비정질 키나아제 억제제 제형 및 이의 사용 방법
EP4247795A1 (en) 2020-11-18 2023-09-27 Deciphera Pharmaceuticals, LLC Gcn2 and perk kinase inhibitors and methods of use thereof
CN113527294A (zh) * 2021-08-25 2021-10-22 都创(上海)医药开发有限公司 Mrtx849化合物的晶型及其制备方法和用途
CN115894404A (zh) * 2021-09-22 2023-04-04 杭州天玑济世生物科技有限公司 一类具有萘胺结构的小分子化合物及其应用
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262088B1 (en) 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
GB9910807D0 (en) 1999-05-10 1999-07-07 Prometic Biosciences Limited Novel detoxification agents and their use
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
WO2001085700A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
JP4510442B2 (ja) 2001-06-26 2010-07-21 ブリストル−マイヤーズ スクイブ カンパニー ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
EP2332924A1 (de) 2001-10-17 2011-06-15 Boehringer Ingelheim Pharma GmbH & Co. KG Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
JP4072615B2 (ja) 2002-03-05 2008-04-09 独立行政法人産業技術総合研究所 配位子を有する複素環化合物及びその製造方法、及びこの複素環化合物を用いる金属元素の固定化膜
RS20050363A (en) 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
CA2531232A1 (en) 2003-07-16 2005-02-10 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
DE602004032446D1 (de) 2003-08-07 2011-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
WO2005118544A2 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
ATE415397T1 (de) 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1835934A4 (en) 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc ENZYME MODULATORS AND TREATMENTS
MX2007008189A (es) 2005-01-07 2007-08-07 Hoffmann La Roche Derivados de [4-(heteroaril)piperazin-1-il]-(fenilo 2,5-sustituido) metanona como inhibidores del transportador de glicina 1(glyt-1) para el tratamiento de trastornos neurologicos y neuropsiquiatricos.
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
CN101484433A (zh) 2006-02-15 2009-07-15 艾博特公司 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
US20090312321A1 (en) 2006-05-15 2009-12-17 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
US20070293494A1 (en) 2006-06-15 2007-12-20 Djung Jane F 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
CN101611035A (zh) 2006-12-28 2009-12-23 大正制药株式会社 吡唑并嘧啶化合物
CA2678639A1 (en) 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
CN101910151A (zh) 2007-10-22 2010-12-08 先灵公司 双环杂环衍生物及其作为gpr119活性调节剂的用途
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
WO2009158373A1 (en) 2008-06-26 2009-12-30 Smithkline Beecham Corporation Inhibitors of akt activity
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EA201170627A1 (ru) 2008-10-29 2011-10-31 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Циклопропанамиды и аналоги, проявляющие противораковые и антипролиферативные активности
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
GEP20146125B (en) 2009-12-17 2014-07-25 Merck Canada Aminopyrimidines as syk inhibitors
RU2012132473A (ru) 2009-12-30 2014-02-10 Селджин Авиломикс,Инк Лиганд-направленная ковалентная модификация белка
RU2012151012A (ru) 2010-04-29 2014-06-10 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием
US8569319B2 (en) 2010-04-29 2013-10-29 Deciphera Pharmaceuticals, LLS Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
JPWO2012033195A1 (ja) 2010-09-10 2014-01-20 京都薬品工業株式会社 複素環化合物
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
US20140179664A1 (en) * 2011-07-28 2014-06-26 Cellzome Limited Heterocyclyl Pyrimidine Analogues As JAK Inhibitors
WO2013078295A2 (en) 2011-11-22 2013-05-30 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
CA2850705C (en) 2011-11-29 2020-03-10 F. Hoffmann-La Roche Ag 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease
CN103958482B (zh) 2011-11-29 2017-06-09 健泰科生物技术公司 作为lrrk2调节剂的氨基嘧啶衍生物
MX353254B (es) 2011-11-30 2018-01-05 Genentech Inc Radioligandos marcados con fluor-18 y carbono-11 para la formacion de imagenes por tomografia de emision de positrones para proteina cinasa 2 de repeticion rica en leucina (lrrk2).
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US9187474B2 (en) 2012-03-07 2015-11-17 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20140073634A1 (en) 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
US9012635B2 (en) 2013-03-15 2015-04-21 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
WO2014145015A2 (en) 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
WO2014145029A2 (en) 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
US9193719B2 (en) 2013-03-15 2015-11-24 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
MX365574B (es) 2013-03-15 2019-06-06 Deciphera Pharmaceuticals Llc 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas.
AU2014233414B2 (en) 2013-03-15 2018-07-12 Deciphera Pharmaceuticals, Llc. N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
CN103242341B (zh) 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
RU2650512C2 (ru) 2013-09-18 2018-04-16 Бейджин Ханми Фармасьютикал Ко., Лтд. Соединение, ингибирующее активности киназ ВТК и/или JAK3
WO2015039613A1 (zh) 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
DK3057943T3 (en) 2013-10-18 2018-07-30 Eisai R&D Man Co Ltd PYRIMIDINE-FGFR4 INHIBITORS
LT3060550T (lt) 2013-10-21 2019-08-12 Merck Patent Gmbh Heteroarilo junginiai, kaip btk inhibitoriai, ir jų panaudojimas
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
US20150284341A1 (en) 2014-04-07 2015-10-08 Catylix, Inc. Fluoroalkyl-substituted derivatives of pyridine, pyrimidine, and pyrazine
EP3185868B1 (en) 2014-08-25 2022-04-06 Salk Institute for Biological Studies Novel ulk1 inhibitors and methods using same
CN107406427A (zh) 2015-02-25 2017-11-28 豪夫迈·罗氏有限公司 炔基醇及其使用方法
US10336734B2 (en) 2015-08-02 2019-07-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ACK1/TNK2 tyrosine kinase
US10738016B2 (en) 2015-10-13 2020-08-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-kinase inhibitors as cancer therapeutics
EP3589284A4 (en) 2017-02-28 2020-12-16 The General Hospital Corporation USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS
EP3630110A1 (en) 2017-05-30 2020-04-08 Deciphera Pharmaceuticals, Inc. Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptoralpha
CN109535132B (zh) * 2017-09-21 2021-07-20 北京赛特明强医药科技有限公司 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CA3089630A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
SG11202008832TA (en) * 2018-04-10 2020-10-29 Neuropore Therapies Inc Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways
FI3902547T3 (fi) 2018-12-28 2023-12-05 Deciphera Pharmaceuticals Llc Csf1r-inhibiittoreita käytettäväksi syövän hoitamisessa
AU2020274011B2 (en) 2019-05-10 2024-02-15 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
TW202108573A (zh) 2019-05-10 2021-03-01 美商迪賽孚爾製藥有限公司 苯基胺基嘧啶醯胺自噬抑制劑及其使用方法
PE20221083A1 (es) 2019-06-17 2022-07-05 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso

Also Published As

Publication number Publication date
JP2022531932A (ja) 2022-07-12
DK3966206T3 (da) 2023-11-13
CN114072397A (zh) 2022-02-18
US11518758B2 (en) 2022-12-06
FI3966206T3 (fi) 2023-10-20
PL3966206T3 (pl) 2024-01-29
IL287795A (en) 2022-01-01
CL2021002953A1 (es) 2022-07-15
RS64755B1 (sr) 2023-11-30
US20200354346A1 (en) 2020-11-12
PT3966206T (pt) 2023-11-10
CO2021016765A2 (es) 2022-04-08
EP4295846A3 (en) 2024-02-28
PE20220592A1 (es) 2022-04-22
WO2020231808A1 (en) 2020-11-19
HRP20231310T1 (hr) 2024-02-02
AU2020274011A1 (en) 2021-11-25
AU2020274011B2 (en) 2024-02-15
EP3966206A1 (en) 2022-03-16
EP3966206B1 (en) 2023-08-09
SG11202112171XA (en) 2021-12-30
LT3966206T (lt) 2023-11-10
SI3966206T1 (sl) 2023-12-29
EP4295846A2 (en) 2023-12-27
BR112021022576A2 (pt) 2022-01-25
TW202108574A (zh) 2021-03-01
KR20220019696A (ko) 2022-02-17
CA3139120A1 (en) 2020-11-19
US20230047915A1 (en) 2023-02-16
ES2962852T3 (es) 2024-03-21

Similar Documents

Publication Publication Date Title
MX2021013662A (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
MX2021013661A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
EP4234551A3 (en) Pyridazinones as parp7 inhibitors
MX2021015628A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2019000200A (es) Agentes antiproliferativos basados en pirimidina.
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
JOP20220087A1 (ar) أمينات ثنائية الحلقة كمثبطات لـ cdk2
SA519400950B1 (ar) Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2022010082A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
MX2021012359A (es) Inhibidores de la vía de señalización de notch y su uso en el tratamiento de cánceres.
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
MX2022009366A (es) Compuestos y usos de estos.
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
EP4218789A3 (en) Compositions for colon cleansing and the treatment of gastrointestnal disorders